摘要
目的 探讨CD4 4 V6、C erbB 2、雌激素受体 (ER)、孕激素受体 (PR)的表达与乳腺癌临床病理生物学行为的关系及其临床意义 ,评价其各自在临床中的作用。方法 采用CD4 4 V6、C erbB 2、ER、PR单克隆抗体对 12 6例原发性乳腺癌组织进行SP免疫组织化学检测 ,并对检测结果进行统计学分析。结果 CD4 4 V6阳性表达率与患者年龄、肿瘤大小、腋淋巴结转移情况、TNM分期及组织学分级无显著相关性 ,而与组织学类型相关 ,单纯癌、硬癌和髓样癌阳性表达率明显高于黏液腺癌和浸润性小叶癌 ;C erbB 2阳性表达率与患者年龄、肿瘤大小、TNM分期、组织学分级及组织学类型无显著相关 ,而与腋淋巴结转移情况相关 ;ER和PR阳性表达率与患者年龄、肿瘤大小、腋淋巴结转移情况、TNM分期、组织学分级及组织学类型无相关性。结论 CD4 4 V6作为判断乳腺癌预后的指标不够理想 ,C erbB 2可作为判断乳腺癌预后的一个指标 ,ER和PR测定的意义在于指导临床治疗方案的选择。
Objective To investigate the expression of CD44 splice variant 6 (CD44 V6),C-erbB-2,estrogen receptor (ER),progesterone receptor (PR) in breast cancer,and to evaluate their respective values in clinic.Methods One hundred and twenty-six cases of primary breast cancer were studied immunohistochemically by monoclonal antibody CD44 V6,C-erbB-2,ER and PR.Antigen retrieval method followed by a routine SP process was employed.Results CD44 V6 expression did not significantly correlate with the patient age,tumor size,axillary lymph node status,TNM staging and histological grading,but significantly correlated with histological type.C-erbB-2 expression had not significant correlation with the patient age,tumor size,TNM staging,histological grading and histological type,but had significant correlation with axillary lymph node status.The expression of ER and PR had not significant correlation with the patient age,tumor size,axillary lymph node status,TNM staging,histological grading and histological type.Conclusion Multivariate analysis revealed that CD44 V6 is not useful for judging the prognosis of breast cancer.C-erbB-2 is useful for judging the prognosis of breast cancer.The significance of detection of ER and PR may be useful for guiding clinical treatment.
出处
《山西医药杂志》
CAS
2005年第2期94-96,共3页
Shanxi Medical Journal